Pharmacogenomic Profiling of Cisplatin-Resistant and -Sensitive Human Osteosarcoma Cell Lines by Multimodal Targeted Next Generation Sequencing

Pharmacogenomic Profiling of Cisplatin-Resistant and -Sensitive Human Osteosarcoma Cell Lines by Multimodal Targeted Next Generation Sequencing

Cisplatin (CDDP) is a drug for high-grade osteosarcoma (HGOS) treatment. Several germline pharmacogenetic studies have revealed associations between single nucleotide polymorphisms (SNPs) and CDDP-based therapy response or CDDP-related toxicity in patients with HGOS. Whether these variants could pla...

Full description

Bibliographic Details
Main Authors:	Claudia Maria Hattinger, Chiara Casotti, Maria Pia Patrizio, Silvia Luppi, Leonardo Fantoni, Katia Scotlandi, Toni Ibrahim, Massimo Serra
Format:	Article
Language:	English
Published:	MDPI AG 2022-10-01
Series:	International Journal of Molecular Sciences
Subjects:	osteosarcoma next generation sequencing cisplatin resistance single nucleotide polymorphism pharmacogenomics
Online Access:	https://www.mdpi.com/1422-0067/23/19/11787

Similar Items

Single-nucleotide polymorphism profiling by multimodal-targeted next-generation sequencing in methotrexate-resistant and -sensitive human osteosarcoma cell lines
by: Chiara Casotti, et al.
Published: (2023-11-01)

Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact
by: Claudia Maria Hattinger, et al.
Published: (2020-06-01)

The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients
by: Hadeel Obiedat, et al.
Published: (2018-07-01)

Impact of ABC Transporters in Osteosarcoma and Ewing’s Sarcoma: Which Are Involved in Chemoresistance and Which Are Not?
by: Massimo Serra, et al.
Published: (2021-09-01)

Drug Resistance in Osteosarcoma: Emerging Biomarkers, Therapeutic Targets and Treatment Strategies
by: Claudia Maria Hattinger, et al.
Published: (2021-06-01)

Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma
by: Claudia Maria Hattinger, et al.
Published: (2023-01-01)

Pharmacogenomics of Pediatric Cardiac Arrest: Cisplatin Treatment Worsened by a Ryanodine Receptor 2 Gene Mutation
by: Angela Maggio, et al.
Published: (2022-02-01)

Cordycepin augments the chemosensitivity of osteosarcoma to cisplatin by activating AMPK and suppressing the AKT signaling pathway
by: Hong-Bo Li, et al.
Published: (2021-12-01)

MNAT1 promotes proliferation and the chemo-resistance of osteosarcoma cell to cisplatin through regulating PI3K/Akt/mTOR pathway
by: Chensheng Qiu, et al.
Published: (2020-12-01)

PINK1 regulates apoptosis of osteosarcoma as the target gene of cisplatin
by: Zhenxing Si, et al.
Published: (2023-02-01)

ITGB3 promotes cisplatin resistance in osteosarcoma tumors
by: Qian Li, et al.
Published: (2023-04-01)

Identification of genes contributing to cisplatin resistance in osteosarcoma cells
by: Mingzhong Xie, et al.
Published: (2023-01-01)

Checkpoint kinase inhibitor AZD7762 enhance cisplatin-induced apoptosis in osteosarcoma cells
by: Jian Zhu, et al.
Published: (2019-07-01)

Effect of Cisplatin Arterial Infusion (CAI) on Primary Nonmetastatic Pelvic Osteosarcoma: A Preliminary Study
by: Hu X, et al.
Published: (2021-02-01)

GTSE1 is possibly involved in the DNA damage repair and cisplatin resistance in osteosarcoma
by: Chaofan Xie, et al.
Published: (2021-12-01)

Pharmacogenomics: what is next?
by: Julia edi Iulio, et al.
Published: (2012-01-01)

The Down-Regulation of MicroRNA-497 Contributes to Cell Growth and Cisplatin Resistance Through PI3K/Akt Pathway in Osteosarcoma
by: Xue-jun Shao, et al.
Published: (2015-07-01)

The efficacy and safety comparison of first-line chemotherapeutic agents (high-dose methotrexate, doxorubicin, cisplatin, and ifosfamide) for osteosarcoma: a network meta-analysis
by: Bin Zhang, et al.
Published: (2020-02-01)

A 3D Collagen-Based Bioprinted Model to Study Osteosarcoma Invasiveness and Drug Response
by: Evelin Pellegrini, et al.
Published: (2022-09-01)

Polysaccharides from Dendrobium officinale inhibit proliferation of osteosarcoma cells and enhance cisplatin-induced apoptosis
by: Xiaofeng Zhang, et al.
Published: (2020-10-01)

Pharmacogenomics in drug-induced cardiotoxicity: Current status and the future
by: Mo-Yun Li, et al.
Published: (2022-10-01)

TIMP3 Overexpression Improves the Sensitivity of Osteosarcoma to Cisplatin by Reducing IL-6 Production
by: Xiu-guo Han, et al.
Published: (2018-04-01)

The pharmacogenomics of lamotrigine (a literature review)
by: Asya M. Azhigova, et al.
Published: (2021-06-01)

p53 inhibits CTR1-mediated cisplatin absorption by suppressing SP1 nuclear translocation in osteosarcoma
by: Lei Yong, et al.
Published: (2023-01-01)

Emerging strategies and applications of pharmacogenomics
by: Milos Patrice M, et al.
Published: (2004-11-01)

Chemotherapy-Related Encephalopathy With Super-Refractory Status Epilepticus in a Child With Osteosarcoma: A Case Report With a Review of Literature
by: Lorenza Di Genova, et al.
Published: (2019-09-01)

Pharmacogenomics in drug discovery and development /
by: Yan, Qing, 1971-
Published: (2008)

MicroRNA-340-5p modulates cisplatin resistance by targeting LPAATβ in osteosarcoma
by: L. Song, et al.

Pharmacogenomics of Cisplatin Sensitivity in Non-small Cell Lung Cancer
by: Maimon C. Rose, et al.
Published: (2014-10-01)

Genetic Variations and Cisplatin Nephrotoxicity: A Systematic Review
by: Zulfan Zazuli, et al.
Published: (2018-09-01)

A review of literature on the pharmacogenomics of single-nucleotide polymorphisms
by: Iffath Ahmed, et al.
Published: (2022-01-01)

Massive Recurrent Chondroblastic Osteosarcoma of Maxilla: A Rare Case Report
by: Dwarkadas Adwani, et al.
Published: (2014-01-01)

Iron-polydopamine coated multifunctional nanoparticle SiO2@PDA/Fe3+-FA mediated low temperature photothermal for chemodynamic therapy of cisplatin-insensitive osteosarcoma
by: Wenbo Yang, et al.
Published: (2023-03-01)

Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo
by: Xiaoqiang Liu, et al.
Published: (2019-12-01)

INTEGRATING PHARMACOGENOMICS INTO CLINICAL PRACTICE
by: Gurinder Johal, et al.
Published: (2016-05-01)

Public Attitudes toward Pharmacogenomic Testing and Establishing a Statewide Pharmacogenomics Database in the State of Minnesota
by: Lusi Zhang, et al.
Published: (2022-09-01)

Vitamin Pharmacogenomics: New Insight into Individual Differences in Diseases and Drug Responses
by: Hai-Yan He, et al.
Published: (2017-04-01)

Pharmacogenomics /
by: Kalow, Werner, et al.
Published: (2005)

Genomics and Therapeutic Vulnerabilities of Primary Bone Tumors
by: Katia Scotlandi, et al.
Published: (2020-04-01)

Clinical Application and Educational Training for Pharmacogenomics
by: Jason W. Guy, et al.
Published: (2020-09-01)